Back to top

G1 Therapeutics (GTHX) in Focus: Stock Moves 8.9% Higher

Read MoreHide Full Article

G1 Therapeutics, Inc. (GTHX - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the company’s recent uptrend – as the stock is now up 99.1% over past one month time frame.

G1 Therapeutics has seen one negative estimate revision over the past two months. The Zacks Consensus Estimate for the current quarter has also revised downward over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.  

G1 Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESPis 0.00%.

G1 THERAPEUTICS Price and Consensus

A better ranked stock in the Medical - Biomedical and Genetics industry is Protagonist Therapeutics, Inc. (PTGX - Free Report) which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is GTHX going up? Or down? Predict to see what others think: Up or Down

Breaking News: Cryptocurrencies Now Bigger than Visa

The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.

Zacks’ has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.

Click here to access these stocks. >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

G1 THERAPEUTICS (GTHX) - free report >>

Protagonist Therapeutics, Inc. (PTGX) - free report >>

More from Zacks Tale of the Tape

You May Like